Sanofi Exit From Sickle Cell Gene Therapy Leaves Sangamo With Difficult Decision

Adds To Hemophilia A Problems

Sanofi’s decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy.

Sangamo
Sanofi's decision means Sangamo has just pharma partner left - Pfizer - among its clinical trial programs. • Source: Alamy

Sanofi is to hand back the rights to Sangamo Therapeutics’s gene-edited cell therapy for sickle cell disease (SCD), SAR445136, after deciding to focus instead on allogeneic cell therapies.

The Paris-headquartered pharma company announced on 6 January that it would return the rights to the candidate during the first...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip